1. Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study 
Prof Andy C Rawstron, PhD, Aloysius Ssemaganda, MSc, Ruth de Tute, PhD, Chi Doughty, PhD, Darren Newton, PhD, Anna Vardi, PhD, Paul A S Evans, PhD, Kostas Stamatopoulos, MD, Roger G Owen, MRCP, Tracy Lightfoot, PhD, Katie Wakeham, PhD, Alex Karabarinde, Gershim Asiki, PhD, Dr Robert Newton, PhD 
The Lancet Haematology 
Volume 4, Issue 7, Pages e334-e340 (July 2017)
DOI: /S (16)
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

2. Figure 1
Prevalence of MBL in the Ugandan and UK cohorts, by B-cell phenotype
(A) Proportion of participants with detectable CLL-type MBL and CD5-negative MBL according to the 2005 diagnostic criteria.22 (B) Proportion of participants with a monoclonal B-cell subset. CLL=chronic lymphocytic leukaemia. MBL=monoclonal B-cell lymphocytosis.
The Lancet Haematology 2017 4, e334-e340DOI: ( /S (16) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

3. Figure 2 Absolute monoclonal B-cell count, by phenotype
CLL=chronic lymphocytic leukaemia. MBL=monoclonal B-cell lymphocytosis.
The Lancet Haematology 2017 4, e334-e340DOI: ( /S (16) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

4. Figure 3 LAIR1 expression pattern in monoclonal CD5-negative B cells
MBL=monoclonal B-cell lymphocytosis.
The Lancet Haematology 2017 4, e334-e340DOI: ( /S (16) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions